← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Hawaii Biotech, Inc.
Aiea, HI
$78,458,272
Total funding
32
Grants
Funding over time
peak $12.1M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$78,458,272 · 32
By mechanism
R44$26,366,203 · 8
N01$26,239,024 · 1
R01$7,417,980 · 1
UC1$6,565,626 · 1
R43$5,602,967 · 19
U01$3,269,254 · 1
Investigators at Hawaii Biotech, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Development of a Therapeutic to Treat Anthrax in Humans$12,124,546
N01 · FY2018 · AI
Development of a Therapeutic to Treat Anthrax in Humans$9,017,116
N01 · FY2020 · AI
Clinical Development of a Dengue Vaccine$6,565,626
UC1 · FY2004 · AI
Recombinant West Nile Virus Vaccine Adjuvanted with SLA-LSQ Optimize Formulation of VSA Adjuvant$2,997,218
N44 · FY2022 · AI
Development of a Therapeutic to Treat Anthrax in Humans$2,888,300
N01 · FY2019 · AI
Development of a Therapeutic to Treat Anthrax in Humans$2,139,810
N01 · FY2023 · AI
Recombinant Subunit Vaccine/Prevention of West Nile Vir*$2,039,391
R44 · FY2005 · NS
Recombinant Subunit Vaccine/Prevention of West Nile Vir*$2,031,665
R44 · FY2006 · NS
Inhibitors of Anthrax Lethal Factor Metalloproteinase$1,997,420
R44 · FY2004 · AI
Recombinant Subunit Vaccine/Prevention of West Nile Vir*$1,954,843
R44 · FY2004 · NS
Inhibitors of Anthrax Lethal Factor Metalloproteinase$1,953,830
R44 · FY2005 · AI
IND Enabling Studies for Small Molecule Anthrax Lethal Factor Inhibitors$1,600,303
R01 · FY2017 · AI
IND Enabling Studies for Small Molecule Anthrax Lethal Factor Inhibitors$1,593,546
R01 · FY2015 · AI
IND Enabling Studies for Small Molecule Anthrax Lethal Factor Inhibitors$1,569,436
R01 · FY2016 · AI
IND Enabling Studies for Small Molecule Anthrax Lethal Factor Inhibitors$1,528,431
R01 · FY2014 · AI
Preclinical Development of a Recombinant Dengue Vaccine$1,399,858
U01 · FY2004 · AI
Inhibitors of Anthrax Lethal Factor Metalloproteinase$1,240,547
R44 · FY2006 · AI
Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses$1,156,549
R44 · FY2015 · AI
IND Enabling Studies for Small Molecule Anthrax Lethal Factor Inhibitors$1,126,264
R01 · FY2013 · AI
Recombinant Subunit Vaccine For Tick-Borne Encephalitis$1,000,000
R44 · FY2010 · AI